Cancer Commons is a non-profit network of patients, physicians, and scientists united by a shared goal—to optimize each patient’s outcome and maximize collective learning to benefit the next patient.
Since our founding in 2011, we have delivered personalized, evidence-based guidance at no charge to more than 10,000 patients and caregivers, supported entirely by philanthropy.
Cancer Commons is staffed by accomplished researchers with PhDs in the molecular biology and pharmacology of cancer and in Artificial Intelligence. They have joined the Commons to apply their knowledge and expertise to help patients research their options in real time using the latest tools of precision oncology.
-
Recurrent Cancer: Unique Treatment Guidance After Cancer Returns—Webinar Recording Now Available
Cancer Commons’ most recent webinar, Recurrent Cancer: Unique Treatment Guidance After Cancer Returns, was held virtually June 14, 2023. During the presentation, Dennis Watson, VP of Business Development of Travera, provided viewers with information and updates on a cancer therapy guidance test designed to predict which cancer drugs are most likely to be effective for individual cancer patients. Travera’s unique technology now applies to many cancers… Read more »
Get to Know Cancer Commons Scientist Adrienne Nugent, PhD
Adrienne Nugent, PhD, has always loved a good puzzle. Growing up, she enjoyed solving math problems, and in college at Duke University, chemistry inspired her puzzle-solving passion. She continued to apply this skill as she earned her PhD in genetics and genomics, also at Duke. Since then, she has found a through-line between her love for puzzles and her love for working directly with… Read more »
A New Technology for Rapid Therapy Guidance: Webinar Recording Now Available
Cancer Commons’ most recent webinar, A New Technology for Rapid Therapy Guidance, was held virtually December 14, 2022. This presentation and Q&A session introduced viewers to a new cancer therapy guidance test that is designed to predict which cancer drugs are most likely to be effective for individual cancer patients. Cancer Commons CEO Rebecca Driscoll introduced Clifford Reid, PhD (Founder and CEO) and Dennis Watson (VP… Read more »
-
It has been extremely gratifying to see how Cancer Commons has brought clarity and greater access to this expertise through its convening and curation.
Keith Flaherty, MD
Cancer Commons Advisor -
What I appreciate the most about Emma is her human goodness and empathy. I have never felt I was just a case for her.
Marilou
Cervical cancer survivor -
This free-of-charge, high-quality information service is a wonderful resource for patients with advanced cancer.
Hope S. Rugo, MD
UCSF Comprehensive Cancer Center -
In a field as complex and dynamic as molecular oncology in 2020, Cancer Commons offers an amazing opportunity for patients with advanced cancer to obtain scientifically up-to-date additional options that may improve both the length and quality of their lives, all free of charge.
Gavin Gordon, PhD
Molecular Pathologist